Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (1724)	12/8/2006 1:51:58 PM
From: Jibacoa	Read Replies (5) \| Respond to of 3722

Mike, Re: arna crxl exel kerx maxy medx mygn rnvo.L ARNA Has closed its downgap of Nov.30 & is now trying to close the Nov.27 one.(The one from Oct.24 is a little far at present.<g> ) bigcharts.marketwatch.com Revenues on the 3rd Q were down more than 40% , but it was able to keep its loss about the same as in 2005. The EL for 2006 is around $2.09/shr vs. $2.24 in 2005 but for 2007 the EL is higher around $2.50/shr. The stock is not yet off its downtrend coming from the Oct.18-Oct.19 double top at the 17.69 level. It seems will have to wait for further reports on its PII on lorcaserin HCl. <g CRXL Has had 4Qs of better revenues, but the losses in the last 3Qs have been higher. For the 9Ms the loss is $1.40/shr vs. $0.40/shr in 2005 & at the present rate the pending 4thQ results aren’t expected to show a much better comparison. It trades around 8.8xBV, with moderate LTD & short ratio around 12x its AvgDV, down some in the last month. It needs to close above its Nov.17 H of 25.46 Will see how the acquisition of SBL Vaccine works out. bigcharts.marketwatch.com KERX Has been doing fairly well, considering its persistent losses & accelerating higher ELs for 2006 & 2007 Yesterday it traded above its Oct.23 H of 14.86 bigcharts.marketwatch.com It trades around 7xBV, has no significant LTD in spite of its pretty good accumulated losses since 1999, the insiders hold close to20% & the institutions more than 35%. the short ratio is around 11x its DAvg.V, down around 15% from last month.Will see how its deal with KHK turns out.<g> Its LTC isn't very "interesting".<g> bigcharts.marketwatch.com EXEL Is now starting to get off from the downtrend coming from the Oct.23 H at 10.55 bigcharts.marketwatch.com It needs to close above its Nov.17 H of 9.26 The insiders have been consistent sellers since June. The 3rdQ revenues were 63% better & was able to trim some its loss, but the EL for 2006 is around $1.15/shr vs. $1.06 in 2005 & the EL of $1.25/shr in 2007 It trades close to 26xBV, with pretty good LTD has a short ratio around 5.5x DavgV, down more than 30% in the last month. The PI results on XL 999 reported last month didn’t show much change from previous. MAXY Has had 2Qs of triple digits improvement on revenues & in the last 2Qs has been trimming its losses. The insiders have done intermittent selling since July.The EL for 2006 is expected to be less than in 2005 but to be higher in 2007. It trades around 1.6xBV with no significant LTD, insiders hold more than 15% & institutions close to 20%. The close ratio is close to 7x its DavgV but down more than 35% in the last month. The news this week on its license to Codexis is “interesting” in view of Codexis deal with Shell& the fact that MAXY owns about 30% of Codexis.<g> It isn't yet off its Sep.16-Sep.17 double top at the 10 level. bigcharts.marketwatch.com MEDX Is the better acting of your group.<g> It started an uptrend on Oct.4 from the 10.42 level & after a little pause has been showing some upgaps (Nov.30 & Dec.7) which hasn’t bothered to close, so far.<g> bigcharts.marketwatch.com It trades around 11.8xBV, has no significant LTD, institutions hold around 25%, insiders more than 5% . the short ratio is around 9x its DavgV, down 11% in last month. The stock traded today above its Jan. H of 16.07 making a new 52wks.H The next resistance is now its Apr.2004 H at 16.83 It has had some good news so fa this month (Its deal with UCSD & the “fast track” designation of its MDX-010 from the FDA ) bigcharts.marketwatch.com Its LTC remains "interesting".<g> bigcharts.marketwatch.com MYGN Is also making a new 52 wks.H as is now trading above its Nov.24 H bigcharts.marketwatch.com It has had 4Qs of double digits improvement on revenues & has been able to trim some its losses. It trades near 5x BV with no significant LTD, insiders hold more than 10% and institutions close to 40%, the short ratio is around 11.5x its Davg.V, down some in the last month. If the stock continues on its present trendeline, the next resistance point is around 34, or its Apr.2002 H of 35 & then the March 2002 H at 38.32 <g > bigcharts.marketwatch.com As of Sep.30 it reportedly had approximately $212M in cash & announced some +results on its PI on Azixa.<g> And its LTC is also "interesting" <g> bigcharts.marketwatch.com I don't follow rnvo.L RAGL Bernard